CagriSema (Cagrilintide + Semaglutide)

Among completers, 91.9% lost at least 5% of body weight versus 31.5% with placebo, with one-third losing 25% or more. An NDA was submitted to the FDA on December 18, 2025, positioning it as the most advanced next-generation obesity therapy. Approval is expected by late 2026 or early 2027; no list price or commercial brand is yet available.